{"id":247622,"date":"2025-09-23T01:04:12","date_gmt":"2025-09-23T01:04:12","guid":{"rendered":"https:\/\/www.europesays.com\/us\/247622\/"},"modified":"2025-09-23T01:04:12","modified_gmt":"2025-09-23T01:04:12","slug":"fda-moves-to-allow-leucovorin-as-treatment-for-autism-symptoms","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/247622\/","title":{"rendered":"FDA moves to allow leucovorin as treatment for autism symptoms"},"content":{"rendered":"

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.<\/p>\n

In a highly unusual move, the Food and Drug Administration reapproved a drug on Monday that stopped being sold more than 25 years ago, part of a push from the Trump administration to identify the causes of and potential treatments for autism<\/a>.\u00a0<\/p>\n

The drug, GSK\u2019s Wellcovorin, is a branded version of leucovorin, a widely available generic drug that\u2019s generally used to help tame the side effects of drugs, including certain cancer treatments. <\/p>\n

President Trump and his health secretary, Robert F. Kennedy Jr., on Monday announced that the administration is exploring leucovorin as an autism therapy during an event on autism at the White House. Health officials also said that Tylenol use during pregnancy could cause autism<\/a>.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…\n","protected":false},"author":3,"featured_media":247623,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[64,69,151,152,153,881,49697,67,132,68],"class_list":{"0":"post-247622","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business","8":"tag-business","9":"tag-donald-trump","10":"tag-fda","11":"tag-pharmaceuticals","12":"tag-policy","13":"tag-public-health","14":"tag-rfk-jr","15":"tag-united-states","16":"tag-unitedstates","17":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115250925769596209","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/247622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=247622"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/247622\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/247623"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=247622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=247622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=247622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}